Fig. 1From: Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinomaStudy design schemes. a Phase I dose escalation trial scheme. b Phase II randomization trial schemeBack to article page